Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage clinical development – potential treatments for Angelman syndrome and complications of extremely premature birth – as well as a preclinical program for diabetic macular edema. Oak Hill has operations in the United States and the United Kingdom.